Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Rational Combinations of Polymyxins with Other Antibiotics.

Bergen PJ, Smith NM, Bedard TB, Bulman ZP, Cha R, Tsuji BT.

Adv Exp Med Biol. 2019;1145:251-288. doi: 10.1007/978-3-030-16373-0_16. Review.

PMID:
31364082
2.

Shifting Gears: The Future of Polymyxin Antibiotics.

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.

Antibiotics (Basel). 2019 Apr 12;8(2). pii: E42. doi: 10.3390/antibiotics8020042. Review.

3.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Deveson Lucas D, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul.

PMID:
30988147
4.

Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study.

Sumon ZE, Berenson CS, Sellick JA, Bulman ZP, Tsuji BT, Mergenhagen KA.

Infect Dis (Lond). 2019 Apr;51(4):287-292. doi: 10.1080/23744235.2018.1533646. Epub 2019 Feb 14.

PMID:
30760062
5.
6.

Concentration-dependent plasma protein binding: Expect the unexpected.

Nation RL, Theuretzbacher U, Tsuji BT; International Society of Anti-Infective Pharmacology (ISAP).

Eur J Pharm Sci. 2018 Sep 15;122:341-346. doi: 10.1016/j.ejps.2018.07.004. Epub 2018 Jul 3. Review.

PMID:
30026170
7.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
8.

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Bulman ZP, Zhao M, Satlin MJ, Chen L, Kreiswirth BN, Walsh TJ, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.

PMID:
29486233
9.

Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Tsuji BT, Fisher J, Boadi-Yeboah R, Holden PN, Sethi S, Pettigrew MM, Murphy TF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01995-17. doi: 10.1128/AAC.01995-17. Print 2018 Feb.

10.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.

Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL.

J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. doi: 10.1093/jac/dkx409.

11.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

12.

Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.

Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT.

J Antimicrob Chemother. 2017 Aug 1;72(8):2297-2303. doi: 10.1093/jac/dkx121.

13.

Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT.

J Antimicrob Chemother. 2017 Jul 1;72(7):1985-1990. doi: 10.1093/jac/dkx070.

14.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
15.

Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.

Maifiah MH, Creek DJ, Nation RL, Forrest A, Tsuji BT, Velkov T, Li J.

Sci Rep. 2017 Mar 30;7:45527. doi: 10.1038/srep45527.

16.

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, Soo Shin B, Kaye KS, Bulitta JB, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.

17.

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Bulman ZP, Satlin MJ, Chen L, Kreiswirth BN, Shin BS, Walsh TJ, Holden PN, Forrest A, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02023-16. doi: 10.1128/AAC.02023-16. Print 2017 Apr.

18.

A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).

Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, Parameswaran GI, Mergenhagen KA, Tsuji BT.

Infect Dis (Lond). 2017 May;49(5):410-416. doi: 10.1080/23744235.2016.1277587. Epub 2017 Jan 24.

PMID:
28116950
19.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr.

20.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01268-16. doi: 10.1128/AAC.01268-16. Print 2017 Mar.

21.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Int J Antimicrob Agents. 2017 Jan;49(1):25-30. doi: 10.1016/j.ijantimicag.2016.07.015. Epub 2016 Sep 1.

PMID:
27931793
22.

Synergistic combinations of polymyxins.

Lenhard JR, Nation RL, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24. Review.

23.

Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.

Brotzki CR, Mergenhagen KA, Bulman ZP, Tsuji BT, Berenson CS.

BMJ Case Rep. 2016 Oct 20;2016. pii: bcr2016215956. doi: 10.1136/bcr-2016-215956.

24.

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J.

Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18. Review.

25.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):719-724. doi: 10.1016/j.ijantimicag.2016.07.024. Epub 2016 Sep 20.

26.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

27.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Oliver A, Tsuji BT, Rayner CR, Nation RL, Landersdorfer CB.

J Antimicrob Chemother. 2016 Nov;71(11):3157-3167. Epub 2016 Aug 11.

28.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Rao GG, Ly NS, Bulitta JB, Soon RL, San Roman MD, Holden PN, Landersdorfer CB, Nation RL, Li J, Forrest A, Tsuji BT.

J Antimicrob Chemother. 2016 Nov;71(11):3148-3156. Epub 2016 Aug 3.

29.

Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Sep;48(3):331-6. doi: 10.1016/j.ijantimicag.2016.06.006. Epub 2016 Jul 12.

30.

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach.

Garonzik SM, Lenhard JR, Forrest A, Holden PN, Bulitta JB, Tsuji BT.

PLoS One. 2016 Jun 10;11(6):e0156131. doi: 10.1371/journal.pone.0156131. eCollection 2016.

31.

Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression.

Soon RL, Lenhard JR, Reilly I, Brown T, Forrest A, Tsuji BT.

J Antibiot (Tokyo). 2017 Jan;70(1):98-101. doi: 10.1038/ja.2016.59. Epub 2016 Jun 8. No abstract available.

PMID:
27270303
32.

Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.

Cheah SE, Johnson MD, Zhu Y, Tsuji BT, Forrest A, Bulitta JB, Boyce JD, Nation RL, Li J.

Sci Rep. 2016 May 19;6:26233. doi: 10.1038/srep26233.

33.

Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Pettigrew MM, Tsuji BT, Gent JF, Kong Y, Holden PN, Sethi S, Murphy TF.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4151-8. doi: 10.1128/AAC.00301-16. Print 2016 Jul.

34.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.

35.

Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.

Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3921-33. doi: 10.1128/AAC.02927-15. Print 2016 Jul.

36.

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80. doi: 10.1128/AAC.02377-15. Print 2016 May.

37.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.

38.

Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1584-91. doi: 10.1128/AAC.02657-15.

39.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT.

Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.

40.

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Bulman ZP, Sutton MD, Ly NS, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2015 Jul;59(7):4343-6. doi: 10.1128/AAC.04629-14. Epub 2015 Apr 27.

41.

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2015 May;70(5):1434-42. doi: 10.1093/jac/dku567. Epub 2015 Feb 23.

42.

Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2015 Apr;59(4):2315-27. doi: 10.1128/AAC.04099-14. Epub 2015 Feb 2.

43.

Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT.

Pharmacotherapy. 2015 Jan;35(1):34-42. doi: 10.1002/phar.1537. Review.

44.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.

PMID:
25459221
45.

Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Lenhard JR, von Eiff C, Hong IS, Holden PN, Bear MD, Suen A, Bulman ZP, Tsuji BT.

Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

46.

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Nation RL, Tsuji BT, Sörgel F, Landersdorfer CB.

J Antimicrob Chemother. 2015 Mar;70(3):818-26. doi: 10.1093/jac/dku437. Epub 2014 Nov 6.

PMID:
25381167
47.

New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.

Rao GG, Ly NS, Haas CE, Garonzik S, Forrest A, Bulitta JB, Kelchlin PA, Holden PN, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2014;58(3):1381-8. doi: 10.1128/AAC.00327-13. Epub 2013 Dec 16.

48.

Consistent global approach on reporting of colistin doses to promote safe and effective use.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Clin Infect Dis. 2014 Jan;58(1):139-41. doi: 10.1093/cid/cit680. Epub 2013 Oct 8. No abstract available.

PMID:
24107410
49.

Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J.

J Antimicrob Chemother. 2013 Oct;68(10):2311-7. doi: 10.1093/jac/dkt207. Epub 2013 Jun 7.

50.

Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.

Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J.

Int J Antimicrob Agents. 2013 Jul;42(1):53-8. doi: 10.1016/j.ijantimicag.2013.02.009. Epub 2013 May 15.

PMID:
23684388

Supplemental Content

Loading ...
Support Center